Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is an anti‑epileptic drug presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures and broader epilepsy management in patients requiring seizure control. The molecule works by modulating neuronal sodium channels, helping to stabilize hyper‑excitable brain tissue.

GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic medication used in the management of seizure disorders.

Partial‑onset seizures: reduces frequency and severity of focal seizures when used alone or as add‑on therapy. Generalized epilepsy: contributes to overall seizure control as part of a comprehensive regimen. Adjunct therapy for refractory epilepsy: provides additional seizure reduction in patients not fully controlled by other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior

When prescribing lacosamide, clinicians should consider several safety aspects.

Renal impairment: assess kidney function and consider dose adjustment. Hepatic impairment: monitor liver enzymes and adjust dose if needed. Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. Pregnancy: risk unknown; use only if benefits outweigh potential risks. Concomitant CNS depressants: monitor for enhanced sedation. Store at room temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma concentrations. - Other sodium‑channel blockers (e.g., phenytoin, lamotrigine): may increase risk of cardiac conduction effects. - CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure and risk of adverse events.

Moderate Interactions (Monitor Closely): - Combination with other antiepileptic drugs: may require therapeutic drug monitoring and dose adjustments. - Alcohol consumption: can potentiate central nervous system depression, leading to increased drowsiness. - QT‑prolonging agents (e.g., macrolide antibiotics): monitor ECG for potential additive cardiac effects.